Moreover, this deficit was ameliorated by treatment of transplanted grafts with glibenclamide (Supplemental Figure 2, A–D), a sulfonylurea used in patients with diabetes with mutations in HNF1A (17). Here, HNF1A is linked to diabetes mellitus.